10.25402/FSOA.10110842.v1
Chaitanya Kumar Thota
Chaitanya Kumar
Thota
Jasmine Bagga
Jasmine
Bagga
Srikanth Chiliveru
Srikanth
Chiliveru
Sakshi Kohli
Sakshi
Kohli
Asmi Bharadwaj
Asmi
Bharadwaj
Minish Jain
Minish
Jain
Shriram Inamdar
Shriram
Inamdar
Bandana Sharan
Bandana
Sharan
Supplementary Figure 1. Substantial remission of Prostate Adenocarcinoma with Dendritic Cell therapy APCEDEN® in combination with chemotherapy
Future Science Group
2019
Prostate adenocarcinoma
Immunotherapy
APCEDEN®
Dendritic cells
interferon gamma
IFNγ
Neutrophil lymphocyte ratio
NLR
Platelet lymphocyte ratio
PLR
Treg
Regulatory T Cells
Nephrology and Urology
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
2019-10-31 16:14:11
Figure
https://future-science-group.figshare.com/articles/figure/Supplementary_Figure_1_Substantial_remission_of_Prostate_Adenocarcinoma_with_Dendritic_Cell_therapy_APCEDEN_in_combination_with_chemotherapy/10110842
<div>Supplementary Figure 1. Substantial remission of Prostate Adenocarcinoma with Dendritic Cell therapy APCEDEN® in combination with chemotherapy</div><div><br></div><div>Phenotypic assessment of dendritic cells before packaging of six doses of APCEDEN® treatment.</div><div><br></div>